[Experimental study on prevention and treatment of bronchial asthma by compound Chinese herbal monomer recipe].
OBJECTIVE
To observe the effect of compound Chinese herbal monomer (CHM) recipe, consisted of ligustrazin (3.75 mg/kg x d), baicalin (7.5 mg/kg x d) and ginkgolide (2 mg/kg x d), on airway atopic inflammation and hyper-responsiveness in asthma.


METHODS
Model guinea pigs of asthma were randomly divided into three groups, the model group, the CHM group and the cromlyn sodium (CS) group, they were treated by atomizing inhalation with normal saline, CHM and CS respectively. The eosinophil count and eosinophil cation protein (ECP) in blood and bronchial alveolar lavage fluid (BALF), and total cell count in BALF were measured and compared. And the effect of treatment on the airway hyperresponsiveness and pathology among groups were compared.


RESULTS
CHM showed significant inhibition on blood eosinophil count and BALF and total cell count in BALF, showing significant difference (P < 0.05 or P < 0.01) as compared with those in the model group. The level of ECP was not different in the various groups. Airway responsiveness determination showed that CHM has significant inhibitory action on it. And the pathology of airway inflammation in the CHM group was significantly milder than that in the model group.


CONCLUSIONS
The compound inhalation liquid consisted of ligustrazin, baicalin and ginkgolide, has the anti-asthmatic airway atopic inflammation and depression on airway hyper-responsiveness, suggesting that components of compound CHM recipe could inhibit the multiple pathogenetic asthmatic inflammation from different angles and on multiple targets, so as to cure asthma effectively.
Dong
Jing-cheng
JC
Institute of Pulmonary and Atopic Diseases by Integrative Chinese and Western Medicine, Huashan Hospital, Fudan University, Shanghai. jcdong2004@hotmail.com
Ni
Jian
J
Gong
Zhao-hua
ZH
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D016535:Bronchial Hyperreactivity / Q000188:drug therapy / Q000517:prevention & control; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D004365:Drugs, Chinese Herbal / Q000494:pharmacology; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D020441:Ginkgo biloba; D006168:Guinea Pigs; D008297:Male; D011719:Pyrazines / Q000494:pharmacology*; D011897:Random Allocation
D018927:Anti-Asthmatic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004365:Drugs, Chinese Herbal; D005419:Flavonoids; D011719:Pyrazines; C038044:baicalin; C017953:tetramethylpyrazine